The Pathogenesis of NASH: Human Studies

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 76-90

  Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Esterification; Fatty acids; Insulin; Lipolysis; Nonalcoholic steatohepatitis (NASH)

Indexed keywords

EID: 33748950780     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch7     Document Type: Chapter

References (74)

1. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of non-alcoholic fatty liver disease. Adv Anat Pathol 2002; 9: 37-51.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Non alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
3. Powell EE, Cooksley WG, Hanson R et al. The natural history of non-alcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 1990; 11: 74-80.
4. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
5. Ground KEV. Prevalence of fatty liver in healthy adults accidentally killed. Aviat Space Environ Med 1984; 55: 59-61.
6. Marcos A, Fisher RA, Ham JM et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69: 2410-5.
7. Garcia Urena MA, Colina Ruiz-Delgado F, Moreno GE et al. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998; 22: 837-44.
8. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
9. Miller J, Carr A, Smith D et al. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000; 14: 2406-7.
10. Pagano G, Pacini G, Musso G et al. Non-alcoholic steato- hepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
11. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepato- logy 2002; 35: 373-9.
12. Marchesini G, Bugianesi E, Forlani G et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
13. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
14. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994; 41: 343-8.
15. Berson A, De B V, Letteron P et al. Steatohepatitis- inducing drugs cause mitochondrial dysfunction and lipidperoxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-74.
16. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38: 32-8.
17. Macdonald GA, Bridle KR, Ward PJ et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominantly in acinar zone 3. J GastroenterolHepatol 2001; 16: 599-605.
18. Seki K, Kitada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
19. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
20. Leclercq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
21. Rao MS, Reddy JK. Peroxisomal p-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55.
22. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000; 174: 160-71.
23. Anthonsen MW, Ronnstrand L, Wernstedt C, Degerman E, Holm C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem 1998; 273: 215-21.
24. Newgard CB, Brady MJ, O'Doherty RM, Saltiel AR. Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes 2000; 49: 1967-77.
25. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992; 54: 885-909.
26. Shimomura I, Matsuda M, Hammer RE et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000; 6: 77-86.
27. Deng X, Cagen LM, Wilcox HG et al. Regulation of the Rat SREBP-1c promoter in primary rat hepatocytes. Biochem Biophys Res Commun 2002; 290: 256-62.
28. Kitamura T, Kitamura Y, Kuroda S et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 1999; 19: 6286-96.
29. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
30. Ferrannini E, Vichi S, Beck-Nielsen H et al. Insulin action and age: European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996; 45: 947-53.
31. Hube F, Hauner H. The role of TNF-a in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999; 31: 626-31.
32. Harris RB. Leptin: much more than a satiety signal. Annu Rev Nutr 2000; 20: 45-75.
33. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 1985; 61: 564-70.
34. Peraldi P, Spiegelman B. TNF-a and insulin resistance: summary and future prospects. Mol Cell Biochem 1998; 182: 169-75.
35. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
36. Roden M, Price TB, Perseghin G et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-65.
37. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-46.
38. Randle PJ, Garland PB, Hales CN, Newholme CA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; i: 785-9.
39. Randle PJ, Priestman DA, Mistry S, Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 1994; 37 (Suppl. 2): S155-61.
40. Morand C, Besson C, Demigne C, Remesy C. Importance of the modulation of glycolysis in the control of lactate metabolism by fatty acids in isolated hepatocytes from fed rats. Arch Biochem Biophys 1994; 309: 254-60.
41. Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-9.
42. Griffin ME, Marcucci MJ, Cline GW et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-4.
43. Warren GB, Tipton KF. The role of acetyl-CoA in the reaction pathway of pig-liver pyruvate carboxylase. Eur J Biochem 1974; 47: 549-54.
44. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 1994; 91: 11012-6.
45. Prentki M, Corkey BE. Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl- CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996; 45: 273-83.
46. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70.
47. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001; 15: 61-78.
48. Tomlinson JW, Bujalska I, Stewart PM, Cooper MS. The role of 11β-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res 2000; 26: 711-22.
49. Bergman RN. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res 1997; 52: 359-85.
50. Himsworth H. Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive subtypes. Lancet 1936; i: 127-30.
51. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease, 1988. Nutrition 1997; 13: 65.
52. Marchesini G, Brizi M, Bianchi G et al. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
53. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
54. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in non-alcoholic steatohep- atitis. Hepatology 2002; 35: 898-904.
55. Bernard S, Touzet S, Personne I et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 995-9.
56. Pessayre D, Mansouri A, Fromenty B. Non-alcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282: G193-9.
57. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohep- atitis. J Hepatol 1999; 31: 430-4.
58. Sladky JT. Histopathological features of peripheral nerves and muscle in mitochondrial disease. Semin Neurol 2001; 21: 293-301.
59. Haque M, Mirshahi F, Campbell-Sargent C et al. Non-alcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondrial DNA depletion [Abstract]. Hepatology 2002; 36: 403.
60. Chalasani N, Gorski JC, Asghar MS et al. Hepatic cytochrome P450 2E1 activity in non-diabetic patients with non-alcoholic steatohepatitis. Hepatology 2003; 37: 544-50.
61. Hotamisligil GS. The role of TNF-a and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-5.
62. Lancaster JR Jr, Laster SM, Gooding LR. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett 1989; 248: 169-74.
63. Barnes PJ, Karin M. Nuclear factor-KB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
64. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor-a and TNF-receptors, p55 and p75, in non-alcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
65. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor-a promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
66. Walston J, Seibert M, Yen C, Cheskin LJ, Andersen RE. Tumor necrosis factor-a 238 and -308 polymorphisms do not associate with traits related to obesity and insulin resistance. Diabetes 1999; 48: 2096-8.
67. Bacon BR, Farahvash MJ, Janney CG, Neuschwander- Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
68. George DK, Goldwurm S, Macdonald GA et al. Increased hepatic iron concentration in non-alcoholic steatohepat- itis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
69. Bonkovsky HL, Jawaid Q, Tortorelli K et al. Nonalcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohep- atitis. J Hepatol 1999; 31: 421-9.
70. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
71. Younossi ZM, Gramlich T, Bacon BR et al. Hepatic iron and non-alcoholic fatty liver disease. Hepatology 1999; 30: 847-50.
72. Chitturi S, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-9.
73. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
74. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with non-alcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003; 124: 866-7.